Schedule a Consultation

Industries We Serve / Hospitals & Health Systems / Transplant Programs

Transplant Program & Centers of Excellence AdvisoryEvery Organ. Every Phase. Every Dollar Accounted For.

Centers of Excellence contracting, organ acquisition economics and program strategy for transplant hospitals and the health systems behind them.

Scroll to explore
  • 49,064U.S. organ transplants in 2025UNOS / OPTN, Jan 2026
  • 109,817Candidates on the national waiting listHRSA / OPTN, Jul 2026
  • 250U.S. transplant hospitalsOPTN membership, Nov 2026
  • 95Kidney transplant hospitals in CMS's IOTA model, year 2CMS, Jul 2026

The Transplant Landscape

Each Organ Is Its Own Business

Volume, waiting lists and the charge profile of each phase of care differ sharply by organ. Select one.

Transplants, 202527,574
Waiting list95,492
Average billed charges per transplant$446,800

Kidney: Billed Charges by Phase of Care

Billed charges by phase: 30 days before, organ procurement, transplant admission, physician services, 180 days after discharge, outpatient drugs.

Transplants and waiting list: HRSA organdonor.gov, OPTN data as of 30 Jul 2026 (2025 calendar year; waiting list is a snapshot of candidates). Charges: Milliman, "2025 U.S. Organ and Tissue Transplants" (Feb 2025)—estimated average billed charges, not payments, from 30 days before admission to 180 days after discharge. Lung charges shown for double lung.

Transplant Economics

Where Transplant Margins Are Won and Lost

Four mechanics decide whether a program funds itself. Select one.

One price, many phases

COE contracts commonly bundle evaluation, the transplant admission and a defined follow-up period into phase-based case rates. Each phase has to be priced against its own cost.

Paid on cost, outside the DRG

Medicare reimburses organ acquisition costs at reasonable cost through the cost report, using the share of usable organs that went to Medicare patients.

42 CFR 412.2(e)(4), 412.113(d); 42 CFR 413 Subpart L

A few cases set the year

A handful of complicated admissions can erase a year of case-rate margin. Outlier thresholds and stop-loss terms decide who carries that risk.

The relationship doesn't end at discharge

Follow-up visits, labs and immunosuppressants continue for years. Medicare Part B-ID has covered immunosuppressants for eligible kidney recipients since 2023.

CMS, Part B Immunosuppressive Drug benefit (effective 1 Jan 2023)

Price the Contract Before You Sign It

Model phase-level margin and outlier exposure against your own cost.

How We Help

Five Ways to Strengthen a Transplant Program

Physicians, nurses and specialists reviewing imaging together around a table

Centers of Excellence Contracting

Our founding discipline, applied to transplant: win and keep COE designations on terms that cover cost.

  • Phase-of-care case rate design and pricing
  • Outlier, stop-loss and carve-out terms
  • COE application and renewal strategy
  • Network and transplant-network negotiations
Flight crew member carrying equipment to a waiting medical helicopter at dusk

Organ Acquisition Cost

Organ acquisition is reimbursed on cost—so the cost center, statistics and usable-organ counts have to hold up.

  • OAC cost center and allocation review
  • Medicare usable-organ ratio support
  • Interim payment and settlement analysis
  • OPO and lab agreement economics
Surgical team in masks working under operating lights in a dimly lit operating room

Program Economics & Performance

A P&L for each organ program, from referral to long-term follow-up—built on phase-level cost, not averages.

  • Organ-level contribution and margin
  • Phase-of-care costing
  • Underpayment recovery on transplant claims
  • Capacity, staffing and OR utilization
Laboratory scientist examining sample tubes under cool blue light

Quality, Regulation & IOTA

The outcomes payers and regulators see—SRTR, Medicare approval and CMS's kidney model—translated into strategy.

  • SRTR program-report interpretation
  • CMS transplant program requirements
  • IOTA model performance and payment
  • OPTN policy change readiness
Patient recovering in a sunlit hospital room, talking with her husband by the window

Growth & Referral Networks

Grow volume where it is sustainable: referral relationships, living donation and new organ programs.

  • Referring nephrology and hepatology networks
  • Living donor program development
  • New organ program feasibility
  • Surgeon and physician alignment

Transplant Advisory Studio

Model the Program Before the Payer Does

Three working models with illustrative defaults. Everything recalculates in your browser.

Case-Rate Inputs (per case, $)

More assumptions
Margin, typical case—
Margin, outlier case—
Expected contract margin / yr—
Without stop-loss—

Rate vs. Cost by Phase, Typical Case ($K)

Case rate and cost by phase of care.

Navy: case rate · Gray: cost. Expected margin = cases × [(1 − outlier share) × typical margin + outlier share × outlier margin]. Outlier admission cost = admission cost × multiple; stop-loss pays the stated % of cost above the threshold. Excludes organ acquisition (often handled separately), professional fees and drugs unless built into the phase rates. Contract structures vary; illustrative only.

Organ Acquisition Inputs

Educational model only—not a Medicare cost report, cost settlement or audit position. It simplifies OAC cost-center rules and usable-organ definitions.
Medicare usable-organ ratio—
Supportable OAC—
Estimated Medicare share—
Estimated settlement—

Settlement Sensitivity ($M)

Medicare usable organsCost −5%As enteredCost +5%
As entered———

Where the Cost Goes ($M)

Organ acquisition cost split between Medicare and other payers.

Medicare share = supportable OAC × (Medicare usable organs ÷ total usable organs). Settlement = Medicare share − interim payments (positive = receivable). Before any applicable payment adjustments. Organ acquisition costs are excluded from the MS-DRG and paid at reasonable cost (42 CFR 412.2(e)(4), 412.113(d); 413 Subpart L).

Program Inputs

Revenue and cost per case ($K)
Total contribution—
Program margin after fixed cost—
Strongest organ—
Weakest organ—

Contribution and Allocated Fixed Cost by Organ ($M)

Contribution and allocated fixed cost by organ program.

Navy/magenta: contribution (volume × (revenue − direct cost)) · Brass: fixed cost allocated by volume share. Allocation by volume is a simplification; real programs allocate by resource use. Excludes downstream and referral revenue.

OrganMargin / caseBreak-even volumeAfter allocation
Kidney———

Your contracts, cost report and claims tell the real story.

Request a Transplant Program Assessment

Policy Watch · 16 November 2026

The Rules Reshaping Transplant Programs

$15,000

IOTA Kidney Model

Up to $15,000 upside or $2,000 downside per Medicare kidney transplant, by performance score. Six years from July 2025.

42 CFR 512.430; CMS
5 Tiers

SRTR Program Reports

Released each January and July; tiers now shown as dial icons since March 2026.

SRTR
2026

OPO Recertification

Recertification decisions under CMS's OPO outcome tiers come at the end of the 2022–2026 cycle; final rule CMS-3409-F issued Oct 2026.

CMS
2023

Part B-ID Coverage

Immunosuppressive drug coverage for eligible kidney recipients after ESRD Medicare ends.

CMS

Medicare vs. Commercial COE Economics

The same transplant is paid two very different ways. Strategy has to work for both.

Traditional MedicareCommercial COE Contract
Transplant admissionMS-DRG paymentNegotiated phase-based case rate
Organ acquisitionReasonable cost via cost report, outside the DRGNegotiated: included or separately paid
Quality gateCMS program approval requirementsPayer COE criteria: volume, SRTR outcomes, cost

Sources: 42 CFR 512.430 (as amended 1 Jun 2026) and CMS IOTA fact sheets; SRTR (Jul 2026); CMS-3409-F (Oct 2026); CMS Part B-ID; 42 CFR 412.2(e)(4), 412.113(d), 482.80. Commercial terms vary by contract.

Our Approach

From Contract Review to Centers of Excellence

A 90-day assessment, then a 12- to 18-month contracting and performance cycle. Select a phase.

Weeks 1–4

Contract inventory, SRTR position, COE designations held and missing.

Weeks 4–9

Phase-of-care cost by organ, outlier history and OAC review.

Weeks 9–13

Case-rate pricing, stop-loss terms and COE application plan.

Months 4–12

Payer and network negotiations, applications and renewals.

Months 9–18

Contract performance tracking, recovery and SRTR monitoring.

Illustrative 18-month workplan.

Illustrative workplan. Timing and outcomes depend on each program.

COE Readiness Check

How Ready Is Your Program for Centers of Excellence?

Twelve questions with sample answers filled in—change them to yours. Scored in your browser; nothing is stored or sent.

Outcomes & Quality
Volume & Access
Cost & Pricing
Contracting & Data
Overall readiness——

Readiness score by domain.

Your Readiness Summary

Answer the questions to build your summary.

Schedule a Transplant Program Consultation

A self-assessment for discussion, not a payer's criteria or a prediction of designation. Scoring: Yes 2, Partly 1, No or not sure 0, equally weighted.

Fulcrum Intelligence

Perspectives on Payer Strategy

Questions, Answered

What Is a Transplant Center of Excellence?

A Center of Excellence is a transplant program a payer or transplant network has designated for its members, usually based on outcomes, volume and cost. Designation can steer patients to the program, typically under negotiated case rates.

How Are Transplant Case Rates Structured?

Commercial transplant contracts commonly set rates by phase of care—evaluation, pre-transplant, the transplant admission and a defined follow-up period—with outlier or stop-loss terms for unusually expensive cases. Structures vary by payer and contract.

How Does Medicare Pay for Organ Acquisition?

Medicare excludes organ acquisition costs from the MS-DRG and pays them at reasonable cost through the hospital's cost report, based on the share of usable organs transplanted into Medicare beneficiaries.

What Do SRTR Program-Specific Reports Measure?

SRTR reports transplant rates, waitlist outcomes, offer acceptance and graft and patient survival for each program, with a five-tier assessment. Reports are released each January and July.

What Is the IOTA Model?

CMS's Increasing Organ Transplant Access Model is a mandatory, six-year kidney transplant model that began in July 2025. Participating hospitals can earn up to $15,000 or owe up to $2,000 per Medicare kidney transplant, based on performance.

How Can a Transplant Program Improve Its Margin?

Margin usually improves through case rates priced to phase-level cost, defined outlier protection, accurate organ acquisition cost reporting, recovered underpayments and volume growth through referral networks and living donation.

Build a Transplant Program That Funds Its Mission

Centers of Excellence contracts, organ acquisition economics and program strategy—from one senior team.